Experimental Drugs Without FDA Approval Are Now Legal in Montana - vice.com
Montana has legalized experimental drugs without FDA approval, potentially affecting pharmaceutical manufacturers' distribution and compliance strategies.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 27, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B) facilities operating or distributing in Montana. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the source.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Montana now permits the use of experimental drugs that have not received FDA approval, creating a legal pathway for unapproved drugs within the state.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B) facilities operating or distributing in Montana.
What you must do
Review current distribution and compliance policies to assess potential exposure to unapproved drug distribution and consider legal counsel for implications.
Deadline
Not specified in the source.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Final Debarment Order: Rahim Shafa; Denial of Hearing
- 5th Circ. Backs FDA, Pharma Cos. In GLP-1 Shortage Fight - Law360
- FDA proposes streamlined requirements for ‘hub-and-spoke’ manufacturing models - BioSpace
- FDA Proposes Foreign Manufacturing Establishment Registration and Product Listing Requirements - regulatoryoversight.com
- Guidance: Compounding Animal Drugs from Bulk Drug Substances: Compounding under CGMP in Federally-Registered Facilities